Personalized medicine: new genomics, old lessons
- PMID: 21706342
- PMCID: PMC3128266
- DOI: 10.1007/s00439-011-1028-3
Personalized medicine: new genomics, old lessons
Abstract
Personalized medicine uses traditional, as well as emerging concepts of the genetic and environmental basis of disease to individualize prevention, diagnosis and treatment. Personalized genomics plays a vital, but not exclusive role in this evolving model of personalized medicine. The distinctions between genetic and genomic medicine are more quantitative than qualitative. Personalized genomics builds on principles established by the integration of genetics into medical practice. Principles shared by genetic and genomic aspects of medicine, include the use of variants as markers for diagnosis, prognosis, prevention, as well as targets for treatment, the use of clinically validated variants that may not be functionally characterized, the segregation of these variants in non-Mendelian as well as Mendelian patterns, the role of gene--environment interactions, the dependence on evidence for clinical utility, the critical translational role of behavioral science, and common ethical considerations. During the current period of transition from investigation to practice, consumers should be protected from harms of premature translation of research findings, while encouraging the innovative and cost-effective application of those genomic discoveries that improve personalized medical care.
References
-
- Agency for Healthcare Research and Quality (2007) Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs), structured abstract. January 2007, Rockville, MD. http://www.ahrq.gov/clinic/tp/cyp450tp.htm. Accessed 27 Jan 2011
-
- American Society of Clinical Oncology, Offit K, Bertagnolli MM, Bombard AT, Come S, Eng C, Garber JE, Joffe S, Greene MH, Tucker MA, Gruber SB, Guillem J, Robson M, Halberg FE, Hampel H, Olopade OI, Rieger OT, Rodriguez-Bigas MA, Tomlinson G, Watson MS, Weber BL, Weitzel J, Wiesner GL (2003) American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 21:2397–2406 - PubMed
-
- American Society of Clinical Oncology, Offit K, Biesecker BB, Burt RW, Clayton EW, Garber JE, Kahn MJE, Lichter A, Lynch P, Watson MS, Weber BL, Wells SA (1996) Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility. J Clin Oncol 14:1730–1736 (discussion 1737–1740, adopted on February 20, 1996) - PubMed
-
- American Society of Clinical Oncology, Robson ME, Storm CD, Weitzel J, Wollins DS, Offit K (2010) American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol 28:893–901 - PubMed
-
- Antoniou AC, Beesley J, McGuffog L, Sinilnikova OM, Healey S, Neuhausen SL, Ding YC, Rebbeck TR, Weitzel JN, Lynch HT. Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res. 2010;70:9742. doi: 10.1158/0008-5472.CAN-10-1907. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources